Molecular PharmaceuticsBioengineeringPeer-reviewed journal article
Polymeric Micellar Nanoparticles Enable Image-guided Drug Delivery in Solid Tumors
Md. Jashim UddiniD, Justin Han-Je LoiD, Mukesh Kumar GuptaiD, Thomas A. WerfeliD, Abu S. AsaduzzamaniD, Connor G. OltmaniD, Eva F. GburiD, Mohammed T. MohyuddiniD, Farhana NazminiD, Md. Saidur RahmaniD, Ahan Jashim, Brenda C. Crews, Philip J. KingsleyiD, Jamie E. KlendworthiD, Lawrence J. MarnettiD, Craig L. DuvalliD, Rebecca S. CookiD
- Citations
- 3
- FWCI
- 0.54
- Field percentile
- top 50%
Abstract
We report the development of a nanotechnology to co-deliver chemocoxib A with a reactive oxygen species (ROS)-activatable and COX-2 targeted pro-fluorescent probe, fluorocoxib Q (FQ) enabling real time visualization of COX-2 and CA drug delivery into solid cancers, using a di-block PPS135-b-POEGA17 copolymer, selected for its intrinsic responsiveness to elevated reactive oxygen species (ROS), a key trait of the tumor microenvironment. FQ and CA were synthesized independently, then co-encapsulated within micellar PPS135-b-POEGA17 co-polymeric nanoparticles (FQ-CA-NPs), and were assessed for cargo concentration, hydrodynamic diameter, zeta potential, and ROS-dependent cargo release. The uptake of FQ-CA-NPs in mouse mammary cancer cells and cargo release was assessed by fluorescence microscopy. Intravenous delivery of FQ-CA-NPs to mice harboring orthotopic mammary tumors, followed by vital optimal imaging, was used to assess delivery to tumors in vivo. The CA-FQ-NPs exhibited a hydrodynamic diameter of 109.2 {+/-} 4.1 nm and a zeta potential ({zeta}) of -1.59 {+/-} 0.3 mV. Fluorescence microscopy showed ROS-dependent cargo release by FQ-CA-NPs in 4T1 cells, decreasing growth of 4T1 breast cancer cells, but not affecting growth of primary human mammary epithelial cells (HMECs). NP-derived fluorescence was detected in mammary tumors, but not in healthy organs. Tumor LC-MS/MS analysis identified both CA (2.38 nmol/g tumor tissue) and FQ (0.115 nmol/g tumor tissue), confirming the FQ-mediated image guidance of CA delivery in solid tumors. Thus, co-encapsulation of FQ and CA into micellar nanoparticles (FQ-CA-NPs) enabled ROS-sensitive drug release and COX-2-targeted visualization of solid tumors.
- organism: mouse
- assay: imaging
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Multifunctional phosphate based nanoparticles as a platform for imaging, targeting and doxorubicin delivery to human breast cancer CD44+ cells.
Priscila Izabel Santos de Tótaro, Betânia Mara Alvarenga, … José Dias Corrêa·bioRxiv·Nov 8, 2021
- Self-amplifying ROS-sensitive SN38 Dimeric Prodrug nanoparticles for Combined Chemotherapy and Ferroptosis in Cancer Treatment
Y. Qin, F. Wang, … K.-i. Kamei·bioRxiv·Jan 22, 2024
- ENHANCING TUMOR PERFUSION AND NANOMEDICINE DELIVERY VIA ENDOGENOUS NITRIC OXIDE RELEASE BY METHYL PALMITATE NANOPARTICLES
Roberto Palomba, Elizabeth L. Isaac, … Paolo Decuzzi·bioRxiv·Mar 4, 2026
- The delivery of nano-formulated drugs to solid tumours is selectively increased by co-application of the vascular disrupting agent CA4P
Annabel Kitowski, Constanze Heise, … Julia Thorn‐Seshold·British Journal of PharmacologyPeer-reviewed·May 3, 2026
- Multivalent Lipid MVL5 Micellar Nanoparticles Exhibit Dramatically Increased Loading of Paclitaxel with PEGylation Enhancing Human Cancer Cell Penetration Depth and Cytotoxicity
William S. Fisher, Aria Ghasemizadeh, … Cyrus R. Safinya·bioRxiv·May 24, 2025
- Co-administration of macropinocytosis inhibitory nanoparticles (MiNP) for enhanced nanoparticle circulation time and target tissue accumulation following subcutaneous injection
T. Stack, Y.-G. Liu, … E. A. Scott·bioRxiv·Aug 26, 2020